2012
DOI: 10.3892/ijmm.2012.921
|View full text |Cite
|
Sign up to set email alerts
|

Immunotherapy for SV40 T/t antigen-induced breast cancer by recombinant adeno-associated virus serotype 2 carrying interleukin-15 in mice

Abstract: Abstract. Human interleukin-15 (hIL15) exerts anticancer effects through the activities of lymphokine-activated killer (LAK) cells. However, its short half-life hinders its clinical application. Recombinant adeno-associated virus serotype 2 (rAAV2) is used for hIL15 gene transfer vectors, because of its low immunogenicity and long-term gene expression in human clinical trials. SV40 T/t antigens are related with many human epithelial cancers and are generally found in human breast cancer. In order to demonstrat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2015
2015
2016
2016

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 40 publications
0
1
0
Order By: Relevance
“…Analogously, therapeutic delivery (vector delivered to tumor-bearing mice) led to both 80% lower tumor metastasis and enhanced mean survival by 41% with no apparent liver toxicity observed. Another group intramuscularly administered AAV2-IL15 to a transgenic model of SV40 T/t antigen-induced breast cancer prior to induction of breast cancer, which stimulated lymphokine-activated killer (LAK) cells, slowed tumor growth (tumor size reached 2500 mm 3 after 33 days vs. 20 days for control) and reduced final tumor size by 30% [132]. …”
Section: Aav Delivery Of Therapeutic Payloads In Preclinical Models Omentioning
confidence: 99%
“…Analogously, therapeutic delivery (vector delivered to tumor-bearing mice) led to both 80% lower tumor metastasis and enhanced mean survival by 41% with no apparent liver toxicity observed. Another group intramuscularly administered AAV2-IL15 to a transgenic model of SV40 T/t antigen-induced breast cancer prior to induction of breast cancer, which stimulated lymphokine-activated killer (LAK) cells, slowed tumor growth (tumor size reached 2500 mm 3 after 33 days vs. 20 days for control) and reduced final tumor size by 30% [132]. …”
Section: Aav Delivery Of Therapeutic Payloads In Preclinical Models Omentioning
confidence: 99%